CareDx, Inc (NASDAQ:CDNA) Shares Bought by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC raised its holdings in CareDx, Inc (NASDAQ:CDNA) by 442.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 6,440 shares of the company’s stock after acquiring an additional 5,253 shares during the period. Nisa Investment Advisors LLC’s holdings in CareDx were worth $77,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. ARK Investment Management LLC increased its holdings in shares of CareDx by 7.7% during the 4th quarter. ARK Investment Management LLC now owns 7,194,722 shares of the company’s stock worth $86,337,000 after buying an additional 515,399 shares during the last quarter. BlackRock Inc. increased its holdings in shares of CareDx by 24.6% during the 2nd quarter. BlackRock Inc. now owns 5,439,512 shares of the company’s stock worth $46,236,000 after buying an additional 1,074,531 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of CareDx by 1.6% during the 3rd quarter. Vanguard Group Inc. now owns 5,065,489 shares of the company’s stock worth $86,214,000 after buying an additional 80,292 shares during the last quarter. State Street Corp increased its holdings in shares of CareDx by 0.7% during the 3rd quarter. State Street Corp now owns 4,246,025 shares of the company’s stock worth $72,267,000 after buying an additional 31,345 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. increased its holdings in shares of CareDx by 3.0% during the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,024,503 shares of the company’s stock worth $21,172,000 after buying an additional 87,378 shares during the last quarter.

CareDx Stock Performance

CareDx stock opened at $8.31 on Friday. CareDx, Inc has a fifty-two week low of $4.80 and a fifty-two week high of $12.93. The firm has a 50 day moving average price of $9.66 and a 200 day moving average price of $9.17. The company has a market capitalization of $430.29 million, a PE ratio of -2.35 and a beta of 1.42.

CareDx (NASDAQ:CDNA) last posted its earnings results on Wednesday, February 28th. The company reported ($2.21) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($1.97). CareDx had a negative net margin of 67.88% and a negative return on equity of 51.40%. The company had revenue of $65.57 million during the quarter, compared to analyst estimates of $63.66 million. During the same quarter last year, the business posted ($0.34) EPS. The firm’s revenue for the quarter was down 20.4% on a year-over-year basis. As a group, equities research analysts forecast that CareDx, Inc will post -1.59 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Stephens restated an “overweight” rating and set a $15.00 price target on shares of CareDx in a report on Wednesday. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $13.50.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.